Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poly-ICLC (Hiltonol) in Malignant Pleural Mesothelioma
NCT04525859Phase 1Completed
- Sponsor
- Oncovir, Inc.
- Start
- Aug 2020
- Primary completion
- Jun 2025
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of poly iclc in malignant pleural mesothelioma (MPM) (2 cohorts), sponsored by Oncovir, Inc. Primary endpoint: Probability of rejecting or accepting the investigational treatment based on DLT rate up to 27 days. Started Aug 2020; status: completed.
02
Drugs
poly iclc
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04525859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525859.